Comera SPAC Presentation Deck

SQore in vivo Data Supports Safety of Caffeine ● ·•) Pre-clinical proof of concept studies further validate use of SQore in SQ drug development Animal studies conducted by the Company to assess SQore formulation viability to deliver mAbs. subcutaneously Study #2 Goals (started 12/2021, completion 2/2022) Study #1: no toxicity from caffeine formulation on the test animals (Sprague Dawley® rats), upon SQ and IV administration Study #2: initiated December 2021, final results expected February 2022; no evidence of local or systemic toxicity reported to-date after test formulation administered to study animals ● Comera Comparison of IV and SQ-administered formulations Determine PK profile and bioavailability of mAb formulations upon different routes of administration Testing a control formulation vs. a caffeine containing mAb formulation Observe the animals (SD rats) for any signs of health effects LIFE SCIENCES Based on data collected-to-date, administered subcutaneously, caffeine-containing mAb formulations have not demonstrated evidence of local or systemic toxicity 19

View entire presentation